Genes and Gene Therapy Topics
|
Gene | Location | Topics
|
ABL1 (
ABL
, JTK7
)
| 9q34.1
|
-Gene Therapy for CML [EXPERIMENTAL]
|
AXIN1 | 16p13.3
|
-AXIN2 and Hepatocellular Carcinoma
|
BAX | 19q13.3-q13.4
|
-BAX Gene Transfer (Experimental)
|
CD33 (
GP67
)
| 19q13.3-q13.4
|
-CD33 Targeted Antibody Chemotherapy in AML
|
CD9 (
p24
, MIC3
, BA2
)
| 12p13
|
-Potential role of CD9 in Gene Therapy / Metastasis Supression
|
CDC42 (
G25K
)
| 1p36.1
|
-CDC42 Inhibitors for Gene Therapy (Experimental)
|
CDKN2A (
P16
, INK4A
, MTS1
)
| 9p21
|
-Experimental Gene Therapy Using CDKN2A Adenovirus Vectors
|
CXADR (
CAR
, AAR3
)
| 21q11.2
|
-CXADR and Cancer Gene Therapy
|
CYP2B (
CYP2B1
)
| 19q13.1-q13.2
|
-CYP2B and Gene Therapy (Experimental)
|
ERBB2 (
HER2
, NEU
)
| 17q11.2-q12
|
-anti-HER2 Monoclonal Antibody in Breast Cancer Treatment
|
EWSR1 (
EWS
)
| 22q12
|
-Antisense EWS-FLI1
|
FANCA (
FAA
, FA1
)
| 16q24.3
|
-Experimental Gene Therapy Approaches using FANCA
|
FANCC (
FAC
, FACC
)
| 9q22.3
|
-Experimental Gene Therapy Approaches using FANCC
|
HRAS | 11p15.5
|
-Ras Inhibitors in Gene Therapy (Experimental)
|
IL2 (
TCGF
)
| 4q26-q27
|
-IL2 in Immuo-chemotherapy
-IL2 in Gene Therapy (Experimental)
|
IL4 | 5q31.1
|
-IL4 Gene Transfer for Melanoma (Experimental)
-Published Trials of IL4 for Human Melanoma
|
IL7 | 8q12-q13
|
-IL7 in Gene Therapy (Experimental)
|
MGMT | 10q26
|
-MGMT and Drug Resistance Gene Therapy
|
MUC1 (
PUM
, PEM
)
| 1q21
|
-MUC1 and Immunotherapy [Experimental]
|
PRDM2 (
RIZ1
)
| 1p36
|
-Potential Role of RIZ1 in Gene Therapy
|
PTGS2 (
COX2
)
| 1q25.2-q25.3
|
-COX-2 Inhibitors in Treatment / prevention of Cancer
|
PTPRC (
CD45
, LCA
, GP180
)
| 1q31-q32
|
-CD45 Targeted Antibody Chemotherapy in AML
|
SLC2A1 (
GLUT1
)
| 1p35-p31.3
|
-Experimental Approaches to GLUT1 Supression
|
TP53 (
p53
, P53
)
| 17p13.1
|
-TP53 Related Gene Therapy Approaches (Experimental)
-TP53 Transfer to Mesothelioma Cells (Experimental)
-TP53 Gene Therapy for Lung Cancer (Experimental)
|
|